EndoBiologics International

EndoBiologics is a clinical-stage biotechnology company focused on the development of oral vaccines to prevent enteric infections, particularly shigellosis. The company utilizes a proprietary platform of live-attenuated bacterial vectors designed to stimulate mucosal and systemic immunity against pathogens like Shigella and Enterotoxigenic Escherichia coli (ETEC). Its lead program, WRSS1, is a live-attenuated Shigella sonnei vaccine that has been evaluated in Phase 1 and Phase 2 clinical trials. EndoBiologics has historically collaborated with the Walter Reed Army Institute of Research (WRAIR) and the University of Maryland to advance its vaccine candidates. While the company was active in clinical development through the mid-2010s, it has recently maintained a low operational profile and is currently considered dormant.